[Federal Register Volume 72, Number 96 (Friday, May 18, 2007)]
[Notices]
[Pages 28075-28076]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-9631]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated August 15, 2006, and published in the Federal 
Register on August 22, 2006, (71 FR 48947), Noramco Inc., Division of 
Ortho-McNeil, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 
19801, made application by renewal, and by separate correspondence 
dated June 2,

[[Page 28076]]

2006, and July 25, 2006, to the Drug Enforcement Administration (DEA) 
to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-Oxide (9053).....................  I
Morphine-N-Oxide (9307)....................  I
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Dihydromorphine (9145).....................  II
Hydrocodone (9193).........................  II
Thebaine (9333)............................  II
Morphine (9300)............................  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The company plans to bulk manufacture the above listed controlled 
substances for sale and distribution to manufacturers for product 
development and formulation.
    By letter dated January 4, 2007, Noramco has withdrawn their 
request for Amphetamine (1100) and Methylphenidate (1724).
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Noramco Inc. to manufacture the listed basic classes of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated Noramco Inc. to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with State and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33(a), the above 
named company is granted registration as a bulk manufacturer of the 
basic classes of controlled substances listed.

    Dated: May 8, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-9631 Filed 5-17-07; 8:45 am]
BILLING CODE 4410-09-P